Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

IntroductionPreviously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations.MethodsPatients were identified from a prospective database developed by Boehringer...

Full description

Bibliographic Details
Main Authors: James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Keunchil Park, Antonio Passaro, Filippo De Marinis, Flavio Solca, Angela Märten, Edward S. Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
afatinib
non-small-cell lung cancer
uncommon EGFR mutations
compound mutations
EGFR exon 20 insertions
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.834704/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.834704/full

Similar Items